Head to head
MOTS-c vs SLU-PP-332
Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.
Verdict
Usually stacked; if you must pick, route decides
What you are actually choosing between
Before anything else: the dataset lists MOTS-c and SLU-PP-332 in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.
Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is metabolic health and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — MOTS-c rates 5/5 for metabolic health and SLU-PP-332 rates 4/5.
The evidence
MOTS-c sits one step firmer: some human data, but it is small, old, or uncontrolled — the human data is observational, not interventional. SLU-PP-332 has animal and cell data only, and no controlled human dosing trials — there are no human trials of any kind. One tier is a real difference but not a decisive one; it should not on its own settle the choice.
How they differ in practice
MOTS-c is a subcutaneous injection; SLU-PP-332 is taken by mouth. That is the difference most people actually feel: MOTS-c means reconstituting a vial and injecting; SLU-PP-332 does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.
No half-life is published for either compound in this dataset. That absence is itself information: it means the pharmacokinetics have not been characterized well enough to quote, so both dosing schedules — twice a week for MOTS-c, once daily for SLU-PP-332 — are convention.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
MOTS-c
A 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Mechanistically it is linked to AMPK activation and the folate / one-carbon pathway. The strong data are preclinical: injected MOTS-c improved insulin sensitivity, reduced diet-induced obesity and improved physical capacity in mice, including in aged animals. Human data is limited and mostly observational rather than interventional — circulating MOTS-c levels have been measured in relation to exercise, age, insulin resistance and a longevity-associated mitochondrial variant, but there is no established human dosing trial and no approved product. The figures here are compounding-pharmacy and community convention scaled off the 10 mg vial that is the usual market size, not trial-derived doses. The starting point is 2.5 mg twice a week; 5 mg once a week is the same weekly total and is run the same way. Vendor guides also describe a daily 0.5-1 mg microdose pattern, which reaches comparable weekly exposure by a different route. Human half-life has not been characterized, so it is left null rather than estimated.
SLU-PP-332
A synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), not a peptide. It is marketed as an "exercise mimetic" because in mice it increased oxidative metabolism, running endurance and fat oxidation and reduced fat gain on a high-fat diet without changing food intake. That is the entire evidence base: preclinical rodent and cell work from academic labs. There are NO human trials, no human pharmacokinetics, no human safety data and no published human dosing whatsoever — nothing here is derived from a study in people. It is sold as 1 mg oral tablets, so the 500-1000 mcg (0.5-1 mg) daily range shown is simply half a tablet to one tablet: a deliberately narrow, conservative reading of vendor packaging, not a validated dose. Human half-life is unknown, so it is left null rather than guessed. It is swallowed as tablets rather than reconstituted, so the reconstitution fields do not apply. Treat every number on this page as the lowest possible confidence.
Side by side
The numbers
| Attribute | MOTS-c | SLU-PP-332 |
|---|---|---|
| Class | Metabolic | Metabolic |
| Routes | Subcutaneous | Oral |
| Dose range | 2.5 mg–5 mg (typical 2.5 mg) | 500 mcg–1 mg (typical 1 mg) |
| Frequency | Twice a week | Once daily |
| Half-life | Not characterized | Not characterized |
| Cycle length | 8 weeks | 8 weeks |
| Experience | Advanced | Advanced |
| Evidence | Limited human data | Animal / cell data only |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: MOTS-c
Goals
Where they overlap, and where they do not
| Goal | MOTS-c | SLU-PP-332 |
|---|---|---|
| metabolic health | MOTS-c: 5/5 | SLU-PP-332: 4/5 |
| fat loss | MOTS-c: 4/5 | SLU-PP-332: 4/5 |
| longevity | MOTS-c: 4/5 | SLU-PP-332: 2/5 |
| muscle growth | MOTS-c: 2/5 | SLU-PP-332: 2/5 |
| recovery and sleepone only | MOTS-c: 2/5 | SLU-PP-332: — |
They overlap on 4 goals and diverge on 1. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.